Investor Presentation Q1FY23

Biosimilars: Overview Leadership in biologics R&D, manufacturing and commercialization built over two decades Driven by high scientific acumen with analytical and clinical capabilities in a complex regulatory setting Expertise in large scale biologics manufacturing across diverse technology platforms Product reach in over 75 countries including US, Europe, Canada, Japan and Australia 8 Approved Products1 Biocon 2 Research & 3☑ Manufacturing sites 25+ CGMP approvals Development sites (2 Bengaluru, 1 Malaysia) (incl. FDA & EMA) BIOCON BIOSIMILARS TARGET ADDRESSABLE MARKET $25 bn $21 bn $16 bn Serve patients through commercial partners and direct sales force in India² FY21 FY22 FY23 $73 bn 3.3x $69 bn $62 bn $42 bn FY24 FY25 FY26 FY27 Reported Innovator + Biosimilar³ Sales (2021) 1 Includes Adalimumab and Etanercept which have been in-licensed by Viatris and Biocon Biologics has economic interest. | 2 Branded Formulations India (BFI) is the commercial platform in India | 3 Only includes products where there has been company reported sales (Biosimilar sales only included for companies that report the numbers) BIOCON LIMITED 13

View entire presentation